ClinicalTrials.gg
CompletedNCT03489343Updated Oct 12, 2021Results posted

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

A Phase 1 interventional study of Sym023 in Metastatic Cancer, Solid Tumor and Lymphoma, sponsored by Symphogen A/S. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-12.

Sponsored by Symphogen A/S · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
1,282nd of 1,866
24 · median 43
Started
2018
with 73 others
Phase 1
710 of 2,057
127 open now
Registered
1,238th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 1,282nd largest by enrollment of the 1,866 interventional ones that give a count, is one of 74 that started in 2018, is one of 710 in phase 1, and was the 1,238th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

Read the detailed description

This study evaluated the preliminary safety, tolerability, and dose-limiting toxicities (DLTs) of Sym023, a recombinant, fully human, anti-T-cell immunoglobulin and mucin-domain containing-3 (anti-TIM-3) monoclonal antibody (mAb). The goal was to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of Sym023 when administered once every 2 weeks (Q2W) by intravenous (IV) infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available. If an MTD was not identified, a maximum administered dose (MAD) was to be determined. Sym023 was given to patients in escalating dose cohorts; each patient was given one fixed dose level.

03

Conditions studied

  • Metastatic Cancer
  • Solid Tumor
  • Lymphoma

Keywords

  • Locally advanced/unresectable
  • Metastatic solid tumor
  • Lymphoma
  • Anti-TIM-3
  • TIM-3
  • TIM3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients, ≥ 18 years of age at the time of obtaining .
  • Documented (- or cytologically-proven) solid tumor that is locally advanced or ; patients with documented lymphomas.
  • Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical or nonresectability of the tumor.
  • to or intolerant of existing therapy(ies) known to provide clinical benefit.
  • Measurable or non- according to v1.1 or RECIL 2017.
  • (ECOG) performance status (PS) of 0 or 1.
  • Not of or who agree to use a highly effective method of during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of (WOCBP) and fertile men with WOCBP-partner(s) not using and not willing to use a highly effective method of .
  • Known, untreated central nervous system (CNS) or , or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
  • Hematologic other than lymphomas.
  • Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable.
  • Active uncontrolled bleeding or a known bleeding diathesis.
  • cardiovascular disease or condition.
  • Significant ocular disease or condition, including history of or inflammatory disorder.
  • Significant pulmonary disease or condition.
  • Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.
  • An active, known, or suspected autoimmune disease, or a documented history of autoimmune disease or syndrome, requiring systemic or other medications.
  • History of significant toxicities associated with previous administration of that necessitated permanent discontinuation of that therapy.
  • Patients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy, with exceptions.
  • Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
  • Known history of (HIV) or known active infection with virus (HBV) or virus (HCV).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sym023 0.03 mg/kg

    Sym023 was administered at a dose of 0.03 mg/kg by intravenous infusion

    Drug: Sym023

  • Experimental
    Sym023 0.1 mg/kg

    Sym023 was administered at a dose of 0.1 mg/kg by intravenous infusion

    Drug: Sym023

  • Experimental
    Sym023 0.3 mg/kg

    Sym023 was administered at a dose of 0.3 mg/kg by intravenous infusion

    Drug: Sym023

  • Experimental
    Sym023 1.0 mg/kg

    Sym023 was administered at a dose of 1.0 mg/kg by intravenous infusion

    Drug: Sym023

  • Experimental
    Sym023 3.0 mg/kg

    Sym023 was administered at a dose of 3.0 mg/kg by intravenous infusion

    Drug: Sym023

  • Experimental
    Sym023 10.0 mg/kg

    Sym023 was administered at a dose of 10.0 mg/kg by intravenous infusion

    Drug: Sym023

  • Experimental
    Sym023 20.0 mg/kg

    Sym023 was administered at a dose of 20.0 mg/kg by intravenous infusion

    Drug: Sym023

Interventions

  • DrugSym023

    Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

    Also known as: Anti-TIM-3

06

What researchers measure

Primary outcomes

  1. Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.

    Assess the safety and tolerability of Sym023 on a Q2W (once every 2 weeks) schedule to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. The MTD was to be determined by those DLTs that occurred during C1 in either more than 1 patient in a 3 to 6 patient cohort or ≥33.3% of patients in the event of an expanded 7 to 12 patient cohort. One patient in the 10.0 mg/kg dose cohort was not evaluable for MTD as she did not complete C1 for a reason other than drug toxicity (i.e., discontinuation after 1 dose due to patient withdrawal of consent). However, this patient was included in the evaluation of other outcomes.

    Time frame: 28 days

Secondary outcomes

  1. Evaluation of the Immunogenicity of Sym023.

    Serum sampling to assess the potential for anti-drug antibody (ADA) formation. The number of patients with positive samples at indicated visits is presented.

    Time frame: Baseline up to 6-months follow-up, approximately 1 year

  2. Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIST v1.1

    OR or SD Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.

    Time frame: 24 months

  3. Evaluation of Objective Response (OR) or Stable Disease (SD) by iRECIST

    OR or SD Assessed by Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.

    Time frame: 24 months

  4. Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIL 2017.

    OR or SD Assessed by Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017)

    Time frame: 24 months

  5. Time to Progression (TTP) of Disease.

    Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type. The numbers shown below correspond to the values related to RECIST v1.1.

    Time frame: 24 months

  6. Area Under the Concentration-time Curve in a Dosing Interval (AUC).

    The AUC after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

    Time frame: From before the start of the infusion to 168 hours after the end of the infusion

  7. Maximum Concentration (Cmax)

    Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

    Time frame: From before the start of the infusion to 168 hours after the end of the infusion

  8. Time to Reach Maximum Concentration (Tmax)

    Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

    Time frame: From before the start of the infusion to 168 hours after the end of the infusion

  9. Trough Concentration (Ctrough)

    Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

    Time frame: From before the start of the infusion to 168 hours after the end of the infusion

  10. Terminal Elimination Half-life (T½)

    Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

    Time frame: From before the start of the infusion to 168 hours after the end of the infusion

  11. Clearance (CL)

    Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

    Time frame: From before the start of the infusion to 168 hours after the end of the infusion

07

Results

Posted Oct 12, 2021

Participant flow

Participant flow — Overall Study
MilestoneSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Started1133376
Completed0000000
Not completed1133376
Withdrew: Documented progressive disease1031354
Withdrew: Adverse event0100010
Withdrew: Withdrawal by subject0001011
Withdrew: Clinical progression0001001

Outcome measures

PrimaryAssessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.

Assess the safety and tolerability of Sym023 on a Q2W (once every 2 weeks) schedule to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1. The MTD was to be determined by those DLTs that occurred during C1 in either more than 1 patient in a 3 to 6 patient cohort or ≥33.3% of patients in the event of an expanded 7 to 12 patient cohort. One patient in the 10.0 mg/kg dose cohort was not evaluable for MTD as she did not complete C1 for a reason other than drug toxicity (i.e., discontinuation after 1 dose due to patient withdrawal of consent). However, this patient was included in the evaluation of other outcomes.

Time frame:
28 days
Reported as:
Number · Number of DLTs
Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.
Number of DLTsSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Assessment of Treatment Emergent Adverse Events (AEs) Meeting Dose-limiting Toxicity (DLT) Criteria.0000000
SecondaryEvaluation of the Immunogenicity of Sym023.

Serum sampling to assess the potential for anti-drug antibody (ADA) formation. The number of patients with positive samples at indicated visits is presented.

Time frame:
Baseline up to 6-months follow-up, approximately 1 year
Reported as:
Count of participants · Participants
Evaluation of the Immunogenicity of Sym023.
ParticipantsSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Cycle 1 days 1 and 150000000
Cycle 2 day 10000000
Cycle 3 days 1 and 150000000
Cycle 4 days 1 and 150000000
Cycle 5 day 10101000
Cycle 6 day 10000000
Cycle 7 day 10100000
End of treatment0111000
1-month follow up0111000
3-month follow up0001000
SecondaryEvaluation of Objective Response (OR) or Stable Disease (SD) by RECIST v1.1

OR or SD Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.

Time frame:
24 months
Reported as:
Count of participants · Participants
Evaluation of Objective Response (OR) or Stable Disease (SD) by RECIST v1.1
ParticipantsSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
OR rate0000000
SD >16 weeks0100002
SD ≤16 weeks0002203
SecondaryEvaluation of Objective Response (OR) or Stable Disease (SD) by iRECIST

OR or SD Assessed by Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST). The number of patients with confirmed or unconfirmed OR (partial or complete response) is presented. Duration of SD for patients with best overall response = SD was defined as the time from the day of first study treatment to the start of radiologic disease progression or death. If the patient did not have a radiological disease progression or death, the duration of SD was defined as the time from the day of first study treatment to the date of the last SD assessment.

Time frame:
24 months
Reported as:
Count of participants · Participants
Evaluation of Objective Response (OR) or Stable Disease (SD) by iRECIST
ParticipantsSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
OR rate0000000
iSD >16 weeks0101101
iSD ≤16 weeks0002104
SecondaryEvaluation of Objective Response (OR) or Stable Disease (SD) by RECIL 2017.

OR or SD Assessed by Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017)

Time frame:
24 months

No measurements were reported for this outcome.

SecondaryTime to Progression (TTP) of Disease.

Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type. The numbers shown below correspond to the values related to RECIST v1.1.

Time frame:
24 months
Reported as:
Median · months
Time to Progression (TTP) of Disease.
monthsSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Time to Progression (TTP) of Disease.1.81 (1.81 to 1.81)7.89 (7.89 to 7.89)1.18 (0.72 to 1.38)3.48 (1.87 to 3.55)1.28 (1.12 to 3.52)1.68 (0.03 to 2.07)5.36 (1.61 to 5.55)
SecondaryArea Under the Concentration-time Curve in a Dosing Interval (AUC).

The AUC after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

Time frame:
From before the start of the infusion to 168 hours after the end of the infusion
Reported as:
Mean · h*μg/mL
Area Under the Concentration-time Curve in a Dosing Interval (AUC).
h*μg/mLSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Area Under the Concentration-time Curve in a Dosing Interval (AUC).70 (70 to 70)176 (176 to 176)878 (680 to 1158)3193 (2449 to 4194)8062 (4498 to 12358)30581 (7039 to 45928)77262 (54275 to 85463)
SecondaryMaximum Concentration (Cmax)

Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

Time frame:
From before the start of the infusion to 168 hours after the end of the infusion
Reported as:
Mean · μg/mL
Maximum Concentration (Cmax)
μg/mLSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Maximum Concentration (Cmax)0.85 (0.85 to 0.85)1.98 (1.98 to 1.98)7.94 (5.67 to 11.56)23.71 (19.87 to 28.30)68.03 (52.88 to 84.16)232.11 (183.26 to 288.01)470.24 (294.82 to 543.46)
SecondaryTime to Reach Maximum Concentration (Tmax)

Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

Time frame:
From before the start of the infusion to 168 hours after the end of the infusion
Reported as:
Mean · hours
Time to Reach Maximum Concentration (Tmax)
hoursSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Time to Reach Maximum Concentration (Tmax)4.5 (4.5 to 4.5)0.6 (0.6 to 0.6)1.2 (0.5 to 2.5)4.5 (4.4 to 4.7)1.8 (0.6 to 2.6)3.4 (0.5 to 8.5)7.3 (0.5 to 20.8)
SecondaryTrough Concentration (Ctrough)

Outcome measure after first dose was derived from observed data. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

Time frame:
From before the start of the infusion to 168 hours after the end of the infusion
Reported as:
Mean · μg/mL
Trough Concentration (Ctrough)
μg/mLSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Trough Concentration (Ctrough)NA (NA to NA)0.16 (0.16 to 0.16)1.26 (0.76 to 1.85)6.39 (4.26 to 9.37)12.88 (4.09 to 26.10)74.33 (37.47 to 116.52)146.96 (101.68 to 189.29)
SecondaryTerminal Elimination Half-life (T½)

Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

Time frame:
From before the start of the infusion to 168 hours after the end of the infusion
Reported as:
Mean · hours
Terminal Elimination Half-life (T½)
hoursSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Terminal Elimination Half-life (T½)NA105.10 (105.10 to 105.10)153.49 (136.70 to 164.11)—140.60 (112.78 to 168.42)185.22 (153.43 to 217.01)203.07 (203.07 to 203.07)
SecondaryClearance (CL)

Outcome measure after first dose was estimated using non-compartmental methods. Blood samples for PK analysis were taken at the following timepoints: before the start of the infusion, at the end of the infusion and at 2, 4, 8, 24, 48 and 168 hours after the end of the infusion. Actual timepoints were recorded.

Time frame:
From before the start of the infusion to 168 hours after the end of the infusion
Reported as:
Mean · mL/h)/kg
Clearance (CL)
mL/h)/kgSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Clearance (CL)—0.501 (0.501 to 0.501)0.364 (0.364 to 0.364)—0.582 (0.582 to 0.582)——

Adverse events

Collected over 24 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sym023 0.03 mg/kg0/1 (0%)0/1 (0%)1/1 (100%)
Sym023 0.1 mg/kg0/1 (0%)1/1 (100%)1/1 (100%)
Sym023 0.3 mg/kg3/3 (100%)0/3 (0%)3/3 (100%)
Sym023 1.0 mg/kg0/3 (0%)0/3 (0%)3/3 (100%)
Sym023 3.0 mg/kg2/3 (66.7%)0/3 (0%)3/3 (100%)
Sym023 10.0 mg/kg1/7 (14.3%)2/7 (28.6%)7/7 (100%)
Sym023 20.0 mg/kg1/6 (16.7%)1/6 (16.7%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
Immune-mediated arthritisMusculoskeletal and connective tissue disorders0/11/10/30/30/30/70/6
Back painMusculoskeletal and connective tissue disorders0/10/10/30/30/30/71/6
Spinal cord compressionNervous system disorders0/10/10/30/30/30/71/6
Pathological fractureMusculoskeletal and connective tissue disorders0/10/10/30/30/31/70/6
Lipase increasedInvestigations0/10/10/30/30/31/70/6
Most frequent other events
Showing 10 of 19
Most frequent other events
EventSym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kg
FatigueGeneral disorders1/11/12/31/31/32/71/6
Lymphocyte count decreasedInvestigations1/10/10/30/30/31/70/6
AnemiaBlood and lymphatic system disorders0/10/11/30/31/31/72/6
ConstipationGastrointestinal disorders0/10/10/31/30/31/71/6
NauseaGastrointestinal disorders0/10/11/30/31/30/71/6
PyrexiaGastrointestinal disorders0/10/10/30/31/31/70/6
HyperbilirubinemiaHepatobiliary disorders0/10/11/31/30/30/70/6
Urinary tract infectionInfections and infestations0/10/10/31/31/30/71/6
PneumoniaInfections and infestations0/10/11/30/30/31/70/6
HypophosphatemiaMetabolism and nutrition disorders0/10/11/31/30/31/71/6

Baseline characteristics

The full analysis set (FAS) comprised all consented patients who had received at least a fraction of 1 dose of study drug. The patients in the FAS contributed to the analyses as allocated to treatment.

Age, Categorical
Age, Categorical(Participants)Sym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kgTotal
<=18 years00000000
Between 18 and 65 years112115516
>=65 years00122218
Age, Continuous
Age, Continuous(years)Sym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kgTotal
Median64 (64 to 64)64 (64 to 64)62 (59 to 67)66 (45 to 70)71 (59 to 72)54 (37 to 76)61 (36 to 74)63 (36 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Sym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kgTotal
Female012234416
Male10110328
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kgTotal
Hispanic or Latino00000000
Not Hispanic or Latino113327623
Unknown or Not Reported00001001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kgTotal
American Indian or Alaska Native00000000
Asian00000303
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000213
White113322517
More than one race00000000
Unknown or Not Reported00001001
Region of Enrollment
Region of Enrollment(participants)Sym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kgTotal
Canada00011215
United States113225519
ECOG PS
ECOG PS(Participants)Sym023 0.03 mg/kgSym023 0.1 mg/kgSym023 0.3 mg/kgSym023 1.0 mg/kgSym023 3.0 mg/kgSym023 10.0 mg/kgSym023 20.0 mg/kgTotal
1112236419
000110125
08

Study locations

4 sites
  • South Texas Accelerated Research Therapeutics (START) Midwest
    Grand Rapids, Michigan 49503, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • NEXT Oncology
    San Antonio, Texas 78240, United States
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jun 2020, 24 months.

Results were first posted in Oct 2021, 1 year 4 months after primary completion.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 24 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2018
First posted
Apr 5, 2018
StartActual
May 24, 2018
Primary completionActual
Jun 3, 2020
CompletionActual
Jun 3, 2020
Results first posted
Oct 12, 2021
Last update
Oct 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03489343
Lead sponsor
Symphogen A/S
Responsible party
Sponsor
First posted
Apr 5, 2018
Start date
May 24, 2018
Primary completion
Jun 3, 2020
Completion
Jun 3, 2020
Results posted
Oct 12, 2021
Last update
Oct 12, 2021

Study contacts

Lillian Siu, MD, FRCPC
principal investigator · Princess Margaret Cancer Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYM-023

Start the discussion